About Lexicon Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lexpharma.com/
Frequently Asked Questions
What is the 52-week range for LXRX?
The 52-week high is $2.68 and the 52-week low is $1.1.
What is the P/E ratio for LXRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for LXRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -40.40%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -147.38%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.89.
Analyst Recommendation Trends
Wall Street analyst consensus for LXRX over the last few months:
Latest LXRX News
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
An analyst at a prominent research firm initiated coverage of the
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities
LX-9211’s novel oral, non-opioid mechanism, positive Phase II data and Phase III progress position it to address unmet neuropathic pain needs and create partnering opportunitiesDublin, Sept. 25, 2026 (GLOBE NEWSWIRE) -- "LX-9211 Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The "LX-9211 Sales Forecast and Market Size Analysis - 2034" report provides a comprehensive assessment of pilavapadin (LX-9211), Lexicon Pharmaceuticals' investigationa
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv
Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 11:20 AM EDTCompany ParticipantsMichael Exton - CEO...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | -89,312 | - | - |
| 2026-06-03 | Swain Judith L | +89,312 | - | - |
| 2026-06-03 | Sullivan Diane E. | -89,312 | - | - |
| 2026-06-03 | Sullivan Diane E. | +89,312 | - | - |
| 2026-06-03 | Cheung Ivan | -89,312 | - | - |
| 2026-06-03 | Cheung Ivan | +89,312 | - | - |
| 2026-06-03 | BARKER SAM L | -89,312 | - | - |
| 2026-06-03 | BARKER SAM L | +89,312 | - | - |
| 2026-06-03 | Amouyal Philippe | -89,312 | - | - |
| 2026-06-03 | Amouyal Philippe | +89,312 | - | - |
| 2026-06-03 | SOBECKI CHRISTOPHER J | -89,312 | - | - |
| 2026-06-03 | SOBECKI CHRISTOPHER J | +89,312 | - | - |
| 2026-06-03 | DEBBANE RAYMOND | -89,312 | - | - |
| 2026-06-03 | DEBBANE RAYMOND | +89,312 | - | - |
| 2026-05-01 | Amouyal Philippe | +43,478 | - | - |
| 2026-05-01 | Amouyal Philippe | +35,714 | - | - |
| 2026-05-01 | BARKER SAM L | +43,478 | - | - |
| 2026-05-01 | BARKER SAM L | +35,714 | - | - |
| 2026-05-01 | Cheung Ivan | +43,478 | - | - |
| 2026-05-01 | Cheung Ivan | +35,714 | - | - |
| 2026-05-01 | Swain Judith L | +43,478 | - | - |
| 2026-05-01 | Swain Judith L | +35,714 | - | - |
| 2026-05-01 | Sullivan Diane E. | +43,478 | - | - |
| 2026-05-01 | Sullivan Diane E. | +35,714 | - | - |
| 2026-05-01 | SOBECKI CHRISTOPHER J | +43,478 | - | - |
| 2026-05-01 | SOBECKI CHRISTOPHER J | +35,714 | - | - |
| 2026-05-01 | DEBBANE RAYMOND | +43,478 | - | - |
| 2026-05-01 | DEBBANE RAYMOND | +35,714 | - | - |
| 2026-04-30 | Artal Group S.A. | -408,435 | - | - |
| 2026-04-30 | Artal Group S.A. | +408,435 | - | - |
| 2026-04-30 | Artal Group S.A. | +20,421,735 | - | - |
| 2026-02-28 | McDermott Wendy | -144,393 | - | - |
| 2026-02-28 | McDermott Wendy | -52,316 | - | - |
| 2026-02-28 | McDermott Wendy | -27,697 | - | - |
| 2026-02-28 | McDermott Wendy | -68,107 | $1.47 | $100,117 |
| 2026-02-28 | McDermott Wendy | +144,393 | - | - |
| 2026-02-28 | McDermott Wendy | +52,316 | - | - |
| 2026-02-28 | McDermott Wendy | +27,697 | - | - |
| 2026-02-28 | Martens Rachel Yap | -67,090 | - | - |
| 2026-02-28 | Martens Rachel Yap | -35,826 | $1.47 | $52,664 |
| 2026-02-28 | Martens Rachel Yap | +67,090 | - | - |
| 2026-02-28 | Granowitz Craig B | -202,260 | - | - |
| 2026-02-28 | Granowitz Craig B | -74,226 | - | - |
| 2026-02-28 | Granowitz Craig B | -35,790 | - | - |
| 2026-02-28 | Granowitz Craig B | -109,098 | $1.47 | $160,374 |
| 2026-02-28 | Granowitz Craig B | +202,260 | - | - |
| 2026-02-28 | Granowitz Craig B | +74,226 | - | - |
| 2026-02-28 | Granowitz Craig B | +35,790 | - | - |
| 2026-02-28 | Gopinathan Suma | -65,640 | - | - |
| 2026-02-28 | Gopinathan Suma | -20,310 | - | - |
| 2026-02-28 | Gopinathan Suma | -14,000 | - | - |
| 2026-02-28 | Gopinathan Suma | -24,338 | $1.47 | $35,777 |
| 2026-02-28 | Gopinathan Suma | +65,640 | - | - |
| 2026-02-28 | Gopinathan Suma | +20,310 | - | - |
| 2026-02-28 | Gopinathan Suma | +14,000 | - | - |
| 2026-02-28 | DeFrancesco Lisa | -128,190 | - | - |
| 2026-02-28 | DeFrancesco Lisa | -24,674 | - | - |
| 2026-02-28 | DeFrancesco Lisa | -74,572 | $1.47 | $109,621 |
| 2026-02-28 | DeFrancesco Lisa | +128,190 | - | - |
| 2026-02-28 | DeFrancesco Lisa | +24,674 | - | - |
| 2026-02-28 | Crum Brian T | -170,163 | - | - |
| 2026-02-28 | Crum Brian T | -33,457 | - | - |
| 2026-02-28 | Crum Brian T | -69,386 | - | - |
| 2026-02-28 | Crum Brian T | -105,019 | $1.47 | $154,378 |
| 2026-02-28 | Crum Brian T | +170,163 | - | - |
| 2026-02-28 | Crum Brian T | +69,386 | - | - |
| 2026-02-28 | Crum Brian T | +33,457 | - | - |
| 2026-02-28 | Coiante Scott M | -160,237 | - | - |
| 2026-02-28 | Coiante Scott M | -54,881 | $1.47 | $80,675 |
| 2026-02-28 | Coiante Scott M | +160,237 | - | - |
| 2026-02-28 | Exton Michael | -503,263 | - | - |
| 2026-02-28 | Exton Michael | -204,831 | $1.47 | $301,102 |
| 2026-02-28 | Exton Michael | +503,263 | - | - |
| 2026-02-25 | DEBBANE RAYMOND | +2,000 | $1.49 | $2,980 |
| 2026-02-23 | DEBBANE RAYMOND | +100,000 | $1.47 | $147,000 |
| 2026-02-20 | DEBBANE RAYMOND | +100,000 | $1.4779 | $147,790 |
| 2026-02-19 | DEBBANE RAYMOND | +50,000 | $1.4393 | $71,965 |
| 2026-02-18 | DEBBANE RAYMOND | +133,688 | $1.32 | $176,468 |
| 2026-02-17 | Artal Group S.A. | +41,290 | $65 | $2,683,850 |
| 2026-02-17 | DEBBANE RAYMOND | +76,857 | $1.3082 | $100,544 |
| 2026-02-13 | DEBBANE RAYMOND | +57,952 | $1.3093 | $75,877 |
| 2026-02-12 | McDermott Wendy | +375,300 | - | - |
| 2026-02-12 | McDermott Wendy | +250,200 | - | - |
| 2026-02-12 | Martens Rachel Yap | +290,620 | - | - |
| 2026-02-12 | Martens Rachel Yap | +193,740 | - | - |
| 2026-02-12 | Granowitz Craig B | +519,920 | - | - |
| 2026-02-12 | Granowitz Craig B | +346,610 | - | - |
| 2026-02-12 | Gopinathan Suma | +357,680 | - | - |
| 2026-02-12 | Gopinathan Suma | +238,450 | - | - |
| 2026-02-12 | DeFrancesco Lisa | +386,300 | - | - |
| 2026-02-12 | DeFrancesco Lisa | +257,530 | - | - |
| 2026-02-12 | Crum Brian T | +449,560 | - | - |
| 2026-02-12 | Crum Brian T | +299,710 | - | - |
| 2026-02-12 | Coiante Scott M | +409,020 | - | - |
| 2026-02-12 | Coiante Scott M | +272,680 | - | - |
| 2026-02-12 | Exton Michael | +1,293,670 | - | - |
| 2026-02-12 | Exton Michael | +862,440 | - | - |
| 2026-02-02 | DEBBANE RAYMOND | +367,145 | $65 | $23,864,425 |
| 2026-02-02 | DEBBANE RAYMOND | +1,538,462 | $1.3 | $2,000,001 |
| 2026-02-02 | DEBBANE RAYMOND | +3,846,154 | $1.3 | $5,000,000 |
| 2026-02-02 | DEBBANE RAYMOND | +18,553,846 | $1.3 | $24,120,000 |